SAT0264 LONG TERM FOLLOW-UP AND OPTIMIZATION OF INFLIXIMAB IN REFRACTORY UVEITIS DUE TO BEHÇET’S DISEASE. MULTICENTER STUDY OF 103 CAUCASIAN PATIENTS

Background: Biologic therapy has improved prognosis of Behcet Disease (BD) uveitis (1-5). Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from small series. No data on optimization has been published Objectives: In a large series of Caucasian patients with refractory uveitis of BD, we assess: a) long-term efficacy and safety; b) IFX optimization when ocular remission was achieved Methods: Multicenter study of IFX-treated patients with BD uveitis refractory to conventional immunosuppressants.103 patients were treated with IFX as 1st biologic as follows: 3-5 mg/kg i.v. at 0, 2, 6 and every 4-8 weeks. The main outcomes were anterior chamber cells, vitritis, retinal vasculitis, macular thickness, visual acuity, and glucocorticoids sparing effect; analysed at baseline, 1st week, 1st and 6th months and 1st and 2nd years. After remission, IFX optimization was performed Results: In whole series (n=103), main outcomes showed a rapid and maintained improvement, reaching remission in 78 patients after a mean IFX duration of 31.5 months. Severe side-effects were observed in 9 patients. Comparative study between optimized and non-optimized groups showed: a) no differences in clinical baseline characteristics; b) similar maintained improvement in most ocular outcomes; c) lower severe adverse events and d) lower IFX cost in optimized group (4826.52 vs 9854.13 euros/patient/year) (Table) Conclusion: IFX seems effective and safe in Caucasian patients with refractory BD uveitis. IFX optimization is effective, safe, and cost-effective References: [1]Martin-Varillas JL. Ophthalmology 2018;125:1444-1451. [2]Atienza-Mateo B: Arthritis Rheumatol. 2019;71:2081-2089 [3]Santos-Gomez M. Clin Exp Rheumatol. 2016;34 (6 Suppl 102): S34-S40 [4]Urruticoechea-Arana A. Rheumatol Int. 2019;39:47-58. [5]Atienza-Mateo B. Rheumatology (Oxford). 2018 1;57:856-864 Disclosure of Interests: Jose Luis Martin-Varillas Grant/research support from: AbbVie, Pfizer, Janssen and Celgene, Speakers bureau: Pfizer and Lilly, Belen Atienza-Mateo: None declared, Vanesa Calvo-Rio Grant/research support from: MSD and Roche, Speakers bureau: AbbVie, Lilly, Celgene, Grunenthal, UCB Pharma, Emma Beltran: None declared, Alfredo Adan: None declared, Elena Aurrecoechea: None declared, Santos Castaneda: None declared, Miguel A Gonzalez-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, J. Luis Hernandez: None declared, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD